Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017203264) HLA TARGETING
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/203264 International Application No.: PCT/GB2017/051483
Publication Date: 30.11.2017 International Filing Date: 25.05.2017
IPC:
A61K 38/00 (2006.01) ,A61P 35/00 (2006.01) ,A61P 37/04 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37
Drugs for immunological or allergic disorders
02
Immunomodulators
04
Immunostimulants
Applicants:
SAVAGE, Philip, Michael [GB/GB]; GB
Inventors:
SAVAGE, Philip, Michael; GB
Agent:
SCRIPT IP LIMITED; Turnpike House 18 Bridge Street FROME Somerset BA11 1BB, GB
RICHARDS, William; GB
Priority Data:
1609380.927.05.2016GB
Title (EN) HLA TARGETING
(FR) CIBLAGE HLA
Abstract:
(EN) The invention relates to a complex comprising a) a polypeptide comprising an effector domain, wherein said effector domain comprises a HLA class I polypeptide, or a fragment comprising a T-cell binding portion thereof; and an attachment means for selectively attaching the polypeptide to a target cell; and b) an antigenic peptide bound or attached to said HLA class I polypeptide or fragment, characterised in that said HLA class I polypeptide or fragment thereof comprises a mutation or mutations conferring an enhanced binding affinity of said HLA class I polypeptide or fragment thereof for a CD8 molecule. The invention also relates to uses, compositions and medical uses.
(FR) L'invention concerne un complexe comprenant a) un polypeptide comprenant un domaine effecteur, ledit domaine effecteur comprenant un polypeptide de HLA de classe I, ou un fragment comprenant une partie de liaison aux lymphocytes T de celui-ci ; et un moyen de fixation pour fixer sélectivement le polypeptide à une cellule cible ; et b) un peptide antigénique lié ou fixé au dit polypeptide ou fragment de HLA de classe I, caractérisé en ce que ledit polypeptide de HLA de classe I ou fragment de celui-ci comprend une mutation ou des mutations conférant une affinité de liaison améliorée au dit polypeptide de HLA de classe I ou fragment de celui-ci pour une molécule CD8. L'invention concerne également des utilisations, des compositions et des utilisations médicales.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)